WBB Securities Downgrades Cleveland BioLabs (CBLI) to Speculative Buy
Tweet Send to a FriendGet Alerts CBLI Hot Sheet
Price: $1.66 +1.22%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade CBLI Now!
WBB Securities downgrades Cleveland BioLabs (Nasdaq: CBLI) from Strong Buy to Speculative Buy.
To see all the upgrades/downgrades on shares of CBLI, visit our Analyst Ratings page.
Cleveland BioLabs, Inc. (CBLI), incorporated on June 5 2003, is a biotechnology company focused on developing biodefense, tissue protection and cancer treatment drugs based on the concept of modulation of cell death for therapeutic benefit.
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Ascendiant Capital Downgrades Buckle, Inc. (BKE) to Sell
- Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference
Create E-mail Alert Related Categories
Downgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
